GlassScriptPhysician profile
James L Floyd
NPI 1336317593
$2,871.29
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $430 · 2021: $1,174 · 2022: $514 · 2023: $381 · 2024: $21.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $402.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.10 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $337.61 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $326.38 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $298.93 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $177.36 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $139.92 | 2019-2023 | |
| Radius Health, INC. | $113.17 | 2019 | |
| Glaxosmithkline, LLC. | $77.93 | 2019-2022 | |
| Eisai INC. | $66.00 | 2021-2022 | |
| Allergan, INC. | $64.57 | 2020 | |
| Novo Nordisk INC | $64.57 | 2020-2022 | |
| Lilly USA, LLC | $61.38 | 2022-2023 | Jardiance |
| Antares Pharma, INC. | $54.57 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $53.08 | 2019-2021 | |
| Abbott Laboratories | $48.21 | 2023 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.42 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $39.49 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $36.59 | 2019-2021 | |
| Astellas Pharma US INC | $35.13 | 2020-2021 | |
| Boston Scientific Corporation | $32.68 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.31 | 2022 | |
| Acerus Pharmaceuticals Corporation | $30.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $28.48 | 2021 | |
| Tolmar, INC. | $28.28 | 2023 | |
| Shire North American Group INC | $27.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.87 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $23.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.19 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $13.17 | 2021 | |
| Genentech USA, INC. | $12.75 | 2019 | |
| Pfizer INC. | $12.75 | 2020 | |
| Clarus Therapeutics INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.